Gene recombinant bone marrow mesenchymal stem cells as a tumor-targeted suicide gene delivery vehicle in pulmonary metastasis therapy using non-viral transfection

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 1, 2014, Pages 257-267

  Zhang, Tian Yuan ^a   Huang, Bing ^a   Yuan, Zhong Yue ^a   Hu, Yu Lan ^a   Tabata, Yasuhiko ^b   Gao, Jian Qing ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

BMSCs; CMV TK GCV; Non viral gene vector; Pulmonary melanoma metastasis; Suicide gene therapy

Indexed keywords

BMSCS; CMV-TK/GCV; GENE VECTORS; MELANOMA METASTASIS; SUICIDE GENE THERAPY;

ANTIVIRAL AGENTS; DERMATOLOGY; DISEASES; ENZYMES; GENE TRANSFER; MOLECULAR BIOLOGY; ONCOLOGY; PATHOLOGY; STEM CELLS; TUMORS;

GENE THERAPY;

COPOLYMER; CYTOMEGALOVIRUS THYMIDINE KINASE; GANCICLOVIR; PULLULAN; SPERMINE; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BYSTANDER EFFECT; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; COCULTURE; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXICITY; GENE TARGETING; GENETIC TRANSFECTION; LUNG METASTASIS; MALE; MELANOMA METASTASIS; MESENCHYMAL STEM CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PH; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; RECOMBINANT GENE; STEM CELL GENE THERAPY; SUICIDE GENE; SUICIDE GENE THERAPY; THERAPY EFFECT; ZETA POTENTIAL;

CYTOMEGALOVIRUS;

BMSCS; CMV-TK/GCV; NON-VIRAL GENE VECTOR; PULMONARY MELANOMA METASTASIS; SUICIDE GENE THERAPY;

ANIMALS; BONE MARROW CELLS; CELL LINE, TUMOR; CELL SURVIVAL; CELL- AND TISSUE-BASED THERAPY; CYTOMEGALOVIRUS; GENE TRANSFER TECHNIQUES; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; NEOPLASMS; THYMIDINE KINASE; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890969331     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.06.003     Document Type: Article

References (48)

1. Aboody K.S., Bush R.A., Garcia E., Metz M.Z., Najbauer J., Justus K.A., et al. Development of a tumor-selective approach to treat metastatic cancer. PLoS One 2006, 1:e23.
2. Hu Y.L., Fu Y.H., Tabata Y., Gao J.Q. Mesenchymal stem cells: a promising targeted-delivery vehicle in cancer gene therapy. J Control Release 2010, 147:154-162.
3. Nakamizo A., Marini F., Amano T., Khan A., Studeny M., Gumin J., et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005, 65:3307-3318.
4. Kim S.M., Lim J.Y., Park S.I., Jeong C.H., Oh J.H., Jeong M., et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008, 68:9614-9623.
5. Cihova M., Altanerova V., Altaner C. Stem cell based cancer gene therapy. Mol Pharm 2011, 8:1480-1487.
6. Griffin M.D., Ritter T., Mahon B.P. Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther 2010, 21:1641-1655.
7. Song C., Xiang J., Tang J., Hirst D.G., Zhou J., Chan K.M., et al. Thymidine kinase gene modified bone marrow mesenchymal stem cells as vehicles for antitumor therapy. Hum Gene Ther 2011, 22:439-449.
8. Deng W.P., Wu C.C., Lee C.C., Yang W.K., Wang H.E., Liu R.S., et al. Serial in vivo imaging of the lung metastases model and gene therapy using HSV1-tk and ganciclovir. J Nucl Med 2006, 47:877-884.
9. Evrard A., Cuq P., Ciccolini J., Vian L., Cano J.P. Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase. Br J Cancer 1999, 80:1726-1733.
10. Weyel D., Sedlacek H.H., Muller R., Brusselbach S. Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy. Gene Ther 2000, 7:224-231.
11. Springer C.J., Niculescu-Duvaz I. Prodrug-activating systems in suicide gene therapy. J Clin Invest 2000, 105:1161-1167.
12. Hamstra D.A., Rehemtulla A. Toward an enzyme/prodrug strategy for cancer gene therapy: endogenous activation of carboxypeptidase A mutants by the PACE/Furin family of propeptidases. Hum Gene Ther 1999, 10:235-248.
13. Wolfe L.A., Mullin R.J., Laethem R., Blumenkopf T.A., Cory M., Miller J.F., et al. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843. Bioconjug Chem 1999, 10:38-48.
14. Bar J., Herbst R.S., Onn A. Targeted drug delivery strategies to treat lung metastasis. Expert Opin Drug Deliv 2009, 6:1003-1016.
15. Greco O., Dachs G.U. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 2001, 187:22-36.
16. Syrigos K.N., Epenetos A.A. Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. Anticancer Res 1999, 19:605-613.
17. Pandha H.S., Martin L.A., Rigg A., Hurst H.C., Stamp G.W., Sikora K., et al. Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol 1999, 17:2180-2189.
18. Cavarretta I.T., Altanerova V., Matuskova M., Kucerova L., Culig Z., Altaner C. Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol Ther 2010, 18:223-231.
19. Matuskova M., Hlubinova K., Pastorakova A., Hunakova L., Altanerova V., Altaner C., et al. HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett 2010, 290:58-67.
20. Ryu C.H., Park K.Y., Kim S.M., Jeong C.H., Woo J.S., Hou Y., et al. Valproic acid enhances anti-tumor effect of mesenchymal stem cell mediated HSV-TK gene therapy in intracranial glioma. Biochem Biophys Res Commun 2012, 421:585-590.
21. Bak X.Y., Yang J., Wang S. Baculovirus-transduced bone marrow mesenchymal stem cells for systemic cancer therapy. Cancer Gene Ther 2010, 17:721-729.
22. Walther W., Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 2000, 60:249-271.
23. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999, 286:2244-2245.
24. Hacein-Bey-Abina S., von Kalle C., Schmidt M., Le Deist F., Wulffraat N., McIntyre E., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003, 348:255-256.
25. Matsuura M., Yamazaki Y., Sugiyama M., Kondo M., Ori H., Nango M., et al. Polycation liposome-mediated gene transfer in vivo. Biochim Biophys Acta 2003, 1612:136-143.
26. Merdan T., Kopecek J., Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 2002, 54:715-758.
27. Nakamura K., Ito Y., Kawano Y., Kurozumi K., Kobune M., Tsuda H., et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004, 11:1155-1164.
28. Cho C.W., Cho Y.S., Kang B.T., Hwang J.S., Park S.N., Yoon D.Y. Improvement of gene transfer to cervical cancer cell lines using non-viral agents. Cancer Lett 2001, 162:75-85.
29. Zhao Q.Q., Chen J.L., Lv T.F., He C.X., Tang G.P, Liang W.Q., et al. N/P ratio significantly influences the transfection efficiency and cytotoxicity of a polyethylenimine/chitosan/DNA complex. Biol Pharm Bull 2009, 32:706-710.
30. Gao J.Q., Zhao Q.Q., Lv T.F., Shuai W.P., Zhou J., Tang G.P., et al. Gene-carried chitosan-linked-PEI induced high gene transfection efficiency with low toxicity and significant tumor-suppressive activity. Int J Pharm 2010, 387:286-294.
31. Jo J., Ikai T., Okazaki A., Yamamoto M., Hirano Y., Tabata Y. Expression profile of plasmid DNA by spermine derivatives of pullulan with different extents of spermine introduced. J Control Release 2007, 118:389-398.
32. He C.X., Li N., Hu Y.L., Zhu X.M., Li H.J., Han M., et al. Effective gene delivery to mesenchymal stem cells based on the reverse transfection and three-dimensional cell culture system. Pharm Res 2011, 28:1577-1590.
33. Miao P.H., He C.X., Hu Y.L., Tabata Y., Gao J.Q., Hu Z.J. Impregnation of plasmid DNA into three-dimensional PLGA scaffold enhances DNA expression of mesenchymal stem cells in vitro. Pharmazie 2012, 67:229-232.
34. Hu Y.L., Huang B., Zhang T.Y., Miao P.H., Tang G.P., Tabata Y., et al. Mesenchymal stem cells as a novel carrier for targeted delivery of gene in cancer therapy based on nonviral transfection. Mol Pharm 2012, 9:2698-2709.
35. Jo J., Okazaki A., Nagane K., Yamamoto M., Tabata Y. Preparation of cationized polysaccharides as gene transfection carrier for bone marrow-derived mesenchymal stem cells. J Biomater Sci Polym Ed 2010, 21:185-204.
36. Diwu Z., Chen C.S., Zhang C., Klaubert D.H., Haugland R.P. A novel acidotropic pH indicator and its potential application in labeling acidic organelles of live cells. Chem Biol 1999, 6:411-418.
37. Ishikawa H., Jo J.I., Tabata Y. Liver anti-fibrosis therapy with mesenchymal stem cells secreting hepatocyte growth factor. J Biomater Sci Polym Ed 2012, 23:2259-2272.
38. Schellmann N., Deckert P.M., Bachran D., Fuchs H., Bachran C. Targeted enzyme prodrug therapies. Mini Rev Med Chem 2010, 10:887-904.
39. Kidd S., Caldwell L., Dietrich M., Samudio I., Spaeth E.L., Watson K., et al. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy 2010, 12:615-625.
40. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986, 315:1650-1659.
41. Barbash I.M., Chouraqui P., Baron J., Feinberg M.S., Etzion S., Tessone A., et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 2003, 108:863-868.
42. Nystedt J., Anderson H., Tikkanen J., Pietila M., Hirvonen T., Takalo R., et al. Cell surface structures influence lung clearance rate of systemically infused mesenchymal stromal cells. Stem Cells 2013, 2:317-326.
43. Pulkkanen K.J., Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol Ther 2005, 12:585-598.
44. Jo J., Yamamoto M., Matsumoto K., Nakamura T., Tabata Y. Liver targeting of plasmid DNA with a cationized pullulan for tumor suppression. J Nanosci Nanotechnol 2006, 6:2853-2859.
45. He C.X., Tabata Y., Gao J.Q. Non-viral gene delivery carrier and its three-dimensional transfection system. Int J Pharm 2010, 386:232-242.
46. He C.X., Zhang T.Y., Miao P.H., Hu Z.J., Han M., Tabata Y., et al. TGF-β1 gene-engineered mesenchymal stem cells induce rat cartilage regeneration using nonviral gene vector. Biotechnol Appl Biochem 2012, 59:163-169.
47. Amano S., Gu C., Koizumi S., Tokuyama T., Namba H. Tumoricidal bystander effect in the suicide gene therapy using mesenchymal stem cells does not injure normal brain tissues. Cancer Lett 2011, 306:99-105.
48. Feldmann R.E., Bieback K., Maurer M.H., Kalenka A., Burgers H.F., Gross B., et al. Stem cell proteomes: a profile of human mesenchymal stem cells derived from umbilical cord blood. Electrophoresis 2005, 26:2749-2758.